Table of Contents:

1 Report Prologue
2 Market Introduction
2.1 Scope of Study
2.2 Research Objective
2.3 List of Assumptions
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Increasing prevalence of chronic diseases
4.2.2 Growing adoption of self-injectable devices
4.2.3 Rising FDA approvals
4.2.4 Drivers Impact Analysis
4.3 Restraints
4.3.1 Risks of cross-contamination
4.3.2 Increasing cost of high-end products
4.3.3 Restraints Impact Analysis
4.4 Opportunity
4.4.1 Increasing campaigns of vaccination in developing economies of the Asia-Pacific region
4.5 Macroeconomic Indicators
4.6 Market Trend
4.6.1 Increasing use of auto-injectors against allergies
5 Market Factor Analysis
5.1 Value Chain Analysis
5.1.1 R&D and Designing
5.1.2 Manufacturing
5.1.3 Distribution & Sales
5.1.4 Post-Sales Review
5.2 Porter's Five Forces Model
5.2.1 Threat of New Entrants
5.2.2 Bargaining Power of Suppliers
5.2.3 Threat of Substitutes
5.2.4 Bargaining Power of Buyers
5.2.5 Intensity of Rivalry
5.3 Investment Opportunities
5.4 Pricing Analysis
5.5 Demand & Supply: Gap Analysis
6 Global Injectable Drug Delivery Devices Market, By Devices
6.1 Introduction
6.2 Conventional Injection Devices
6.3 Self-Injection Devices
7 Global Injectable Drug Delivery Devices Market, By Therapeutic Application
7.1 Introduction
7.2 Autoimmune Diseases
7.3 Hormonal Disorders
7.4 Cancer
8 Global Injectable Drug Delivery Devices Market, By Usage Pattern
8.1 Introduction
8.2 Curative pattern
8.3 Immunization
9 Global Injectable Drug Delivery Devices Market, By Site of Delivery
9.1 Introduction
9.2 Intramuscular
9.3 Subcutaneous
9.4 Intra Dermal
10 Global Injectable Drug Delivery Devices Market, By Distribution Channel
10.1 Introduction
10.2 Hospital & Retail Pharmacies
10.3 Online Platforms
11 Global Injectable Drug Delivery Devices Market, By Facility of Use
11.1 Introduction
11.2 Hospitals and Clinics
11.3 Home Care Settings
12 Global Injectable Drug Delivery Devices Market, By Region
12.1 Introduction
12.2 Americas
12.2.1 North America
12.2.1.1 U.S
12.2.1.2 Canada
12.2.1.3 South America
12.3 Europe
12.3.1 Western Europe
12.3.1.1 Germany
12.3.1.2 U.K
12.3.1.3 France
12.3.1.4 Italy
12.3.1.5 Spain
12.3.1.6 Rest of Western Europe
12.3.2 Eastern Europe
12.4 Asia Pacific
12.4.1 Japan
12.4.2 China
12.4.3 India
12.4.4 Republic of Korea
12.4.5 Australia
12.4.6 Rest of Asia Pacific
12.5 Middle East & Africa
12.5.1 Middle East
12.5.2 Africa
13 Competitive Landscape
13.1 Introduction
14 Company Profile
14.1 Eisai Co., Ltd.
14.1.1 Company Overview
14.1.2 Financial Overview
14.1.3 Products Offering
14.1.4 Key Developments
14.1.5 SWOT Analysis
14.1.6 Key Strategy
14.2 Antares Pharma
14.2.1 Company Overview
14.2.2 Financial Overview
14.2.3 Products Offering
14.2.4 Key Developments
14.2.5 SWOT Analysis
14.2.6 Key Strategy
14.3 AstraZeneca
14.3.1 Company Overview
14.3.2 Financial Overview
14.3.3 Pipeline Products
14.3.4 Key Developments
14.3.5 SWOT Analysis
14.3.6 Key Strategy
14.4 Becton, Dickinson and Company
14.4.1 Company Overview
14.4.2 Financial Overview
14.4.3 Products Offering
14.4.4 Key Developments
14.4.5 SWOT Analysis
14.4.6 Key Strategy
14.5 Eli Lilly and Company
14.5.1 Company Overview
14.5.2 Financial Overview
14.5.3 Products Offering
14.5.4 Key Developments
14.5.5 SWOT Analysis
14.5.6 Key Strategy
14.6 F. Hoffmann-La Roche AG
14.6.1 Company Overview
14.6.2 Financial Overview
14.6.3 Products Offering
14.6.4 Key Developments
14.6.5 SWOT Analysis
14.6.6 Key Strategy
14.7 Johnson & Johnson Services Inc.
14.7.1 Company Overview
14.7.2 Financial Overview
14.7.3 Products Offering
14.7.4 Key Developments
14.7.5 SWOT Analysis
14.7.6 Key Strategy
14.8 Mylan N.V.
14.8.1 Company Overview
14.8.2 Financial Overview
14.8.3 Products Offering
14.8.4 Key Developments
14.8.5 SWOT Analysis
14.8.6 Key Strategy
14.9 Novartis AG
14.9.1 Company Overview
14.9.2 Financial Overview
14.9.3 Products Offering
14.9.4 Key Developments
14.9.5 SWOT Analysis
14.9.6 Key Strategy
14.1 Novo Nordisk
14.10.1 Company Overview
14.10.2 Financial Overview
14.10.3 Products Offering
14.10.4 Key Developments
14.10.5 SWOT Analysis
14.10.6 Key Strategy
14.11 Pfizer Inc.
14.11.1 Company Overview
14.11.2 Financial Overview
14.11.3 Products Offering
14.11.4 Key Developments
14.11.5 SWOT Analysis
14.11.6 Key Strategy
14.12 Sanofi
14.12.1 Company Overview
14.12.2 Financial Overview
14.12.3 Products Offering
14.12.4 Key Developments
14.12.5 SWOT Analysis
14.12.6 Key Strategy
14.13 Teva Pharmaceutical Industries Ltd
14.13.1 Company Overview
14.13.2 Financial Overview
14.13.3 Products Offering
14.13.4 Key Developments
14.13.5 SWOT Analysis
14.13.6 Key Strategy
14.14 Inovio Pharmaceuticals Inc.
14.14.1 Company Overview
14.14.2 Financial Overview
14.14.3 Products Offering
14.14.4 Key Developments
14.14.5 SWOT Analysis
14.14.6 Key Strategy
15 Appendix
15.1 Discussion Blue Print